Macular Degeneration Agents Need Randomized Trials, Medicare Panel Says
Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, the Centers for Medicare & Medicaid Services' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore
You may also be interested in...
Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011